| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3974978 | Taiwanese Journal of Obstetrics and Gynecology | 2016 | 7 Pages |
ObjectiveEpithelial ovarian cancer is the most lethal gynecologic cancer worldwide and chemoresistance is one of the major causes of treatment failure. We investigated whether ERCC1, TAU, TOPO2A, TOPO1, P53, and C-MYC expression could be used as predictors for treatment outcomes.Materials and methodsImmunohistochemical staining was used to examine the expression of these biomarkers in resected tumor specimens from 38 patients treated in our institute. Clinicopathological data including demographics, staging, histological type, treatment response, expression of the biomarkers, and patient outcomes were analyzed.ResultsThe median follow-up period was 47.5 months (range, 10–135 months) and the median overall survival was 56.0 months. Patients who did not have expression of ERCC1, and those who had expression of TOPO1 had significantly better overall survival. Cox regression analysis also confirmed that these two biomarkers were significant independent factors predicting survival (ERCC1, hazard ratio 5.51, 95% confidence interval: 2.02–14.00, p = 0.001; TOPO1, hazard ratio 0.22, 95% confidence interval: 0.06–0.77, p = 0.017).ConclusionWe concluded that poor overall survival was significantly associated with positive ERCC1 and negative TOPO1 expression. The results might be the consequence of chemoresistance to platinum and camptothecins, both of which are commonly used regimens in the treatment of epithelial ovarian cancer.
